Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.
Status:
Suspended
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, 1:1, non-comparative phase II trial. Patients with early
stage NSCLC will be randomized between ARM A: neoadjuvant afatinib followed by surgery and
ARM B: immediate surgery with curative intent.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC